Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 5/20 | 0.55 |
| ▸ | TYK2 | P29597 | 5/20 | 0.55 |
| ▸ | JAK3 | P52333 | 3/20 | 0.55 |
| ▸ | JAK2 | O60674 | 10/20 | 0.51 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.51 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.51 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.50 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4457899 | 0.87 | JAK1 (0.68) | JAK1TYK2JAK3JAK2CCNB2 | |
| SCHEMBL1250806 | 0.86 | CCNB2 (0.67) | JAK1TYK2JAK3JAK2CCNB2 | |
| SCHEMBL1251181 | 0.78 | F2 (0.60) | JAK1TYK2JAK3JAK2CCNB2 | |
| SCHEMBL1248143 | 0.78 | CCNB2 (0.77) | JAK1TYK2JAK3JAK2CCNB2 | |
| SCHEMBL7484727 | 0.76 | JAK1 (0.65) | JAK1TYK2JAK3JAK2CCNB2 | |
| SCHEMBL6102916 | 0.76 | CCNB2 (0.87) | JAK1TYK2JAK3JAK2CCNB2 | |
| SCHEMBL1167929 | 0.75 | CCNB2 (0.65) | JAK1TYK2JAK3JAK2CCNB2 | |
| SCHEMBL1248356 | 0.75 | CCNB2 (0.65) | JAK1TYK2JAK3JAK2CCNB2 | |
| SCHEMBL1249224 | 0.75 | CCNB2 (0.65) | JAK1TYK2JAK3JAK2CCNB2 | |
| SCHEMBL1250439 | 0.75 | JAK2 (0.79) | JAK1TYK2JAK3JAK2CCNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312390-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | ALCON, INC. (CH) | 2009-12-17 | — | — | US | claimed |
| CN-101380319-A | Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma | ALCON INC (CH) | 2009-03-11 | — | — | CN | claimed |
| EP-1430120-A4 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | ALCON INC (CH) | 2007-06-20 | — | — | EP | claimed |
| CN-1561393-A | Inhibitors of glycogen synthase kinase-3 (GSK-3) for the treatment of glaucoma | ALCON INC (CH) | 2005-01-05 | — | — | CN | claimed |
| US-20040186159-A1 | Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma | NOVARTIS AG (CH) | 2004-09-23 | — | — | US | claimed |
| EP-1430120-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | Alcon, Inc. (CH) | 2004-06-23 | — | — | EP | claimed |
| WO-2003027275-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | ALCON, INC. (CH) | 2003-04-03 | — | — | WO | claimed |
| EP-1200415-A1 | DIAMINO-1,2,4-TRIAZOLE-CARBOXYLIC ACID DERIVATIVES AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2002-05-02 | — | — | EP | claimed |
| WO-2001009106-A1 | DIAMINO-1,2,4-TRIAZOLE-CARBOXYLIC AND DERIVATIVES AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-02-08 | — | — | WO | claimed |
| EP-2281560-A1 | Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucomatous optic neuropathy | Alcon, Inc. (CH) | 2011-02-09 | — | — | EP | disclosed |
| US-20090312390-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | ALCON, INC. (CH) | 2009-12-17 | — | — | US | disclosed |
| US-7598288-B2 | Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma | ALCON, INC. (CH) | 2009-10-06 | — | — | US | disclosed |
| CN-101380319-A | Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma | ALCON INC (CH) | 2009-03-11 | — | — | CN | disclosed |
| EP-1430120-A4 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | ALCON INC (CH) | 2007-06-20 | — | — | EP | disclosed |
| CN-1561393-A | Inhibitors of glycogen synthase kinase-3 (GSK-3) for the treatment of glaucoma | ALCON INC (CH) | 2005-01-05 | — | — | CN | disclosed |
| US-20040186159-A1 | Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma | NOVARTIS AG (CH) | 2004-09-23 | — | — | US | disclosed |
| EP-1430120-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | Alcon, Inc. (CH) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003027275-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | ALCON, INC. (CH) | 2003-04-03 | — | — | WO | disclosed |
| EP-1200415-A1 | DIAMINO-1,2,4-TRIAZOLE-CARBOXYLIC ACID DERIVATIVES AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001009106-A1 | DIAMINO-1,2,4-TRIAZOLE-CARBOXYLIC AND DERIVATIVES AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186159-A1 | Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma | GSK3B, GSK3A, GSKIP | JAK1 3044/4885TYK2 2654/4885JAK3 662/4885 |
| US-20090312390-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | GSK3B, GSK3A, GSKIP | JAK1 3044/4885TYK2 2654/4885JAK3 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.